Background: Recent data suggest antibiotic-related harm occurs in 1 in 5 hospitalized patients. The purpose of this study was to critically evaluate potential adverse-drug-events (ADE) associated with antimicrobial administration in hospitalized family medicine (FAM) patients.
Methods: Retrospective cohort of adults receiving antimicrobial therapy for respiratory, urinary, and skin infection on an inpatient FAM ward between Jan-Mar 2017/18. Primary endpoint: potential ADEs up to 30 days post-therapy, identified using inpatient and outpatient electronic medical records. ADEs were classified as mild, moderate, or severe; Naranjo scores were used to classify causality. Other endpoints included risk associated with ADE, subsequent 30-day readmissions, and infections due to multi-drug resistant organisms up to 90-days post-therapy.
Results: 1499 antibiotic days were assessed in 150 hospitalized adults. Fifty-four patients with at least one potential ADE (68 total) were identified. By Naranjo score, 10 (6.7%) patients had ÒprobableÓ antibiotic related ADEs (score 5—8), all others were ÒpossibleÓ (score 1—4). Excluding patients with diarrhea receiving concomitant laxatives, 36 patients (24%) suffered from 50 potential ADEs, approximately 3.33 per 100 antibiotic days (Table 1). Thirteen (9.3%) had serious ADEs; 6 were receiving concomitant medications which may have contributed to harm, primarily nephrotoxins (5/6). Alteration of antimicrobial therapy was attributed to ADEs in 12/54 cases (22.2%) while 6 (11.1%) led to 30-day hospital or emergency department (ED) revisits. ADEs were not associated with any specific antimicrobial. Patients with ADEs were more likely to have ED/hospital revisits (OR= 2.42 [1.16—5.05]) and receive more total antibiotic days (11 [6—15] vs 8 days [6—12 days], p=0.036) compared to those who did not.
Conclusion: 1 in 4 hospitalized FAM patients receiving antimicrobials experienced potential ADE. While varying in nature and severity, antimicrobial ADEs contribute to serious harm. These findings underscore need for improved awareness and judicious use.
N. J. Mercuro,
R. Vemulapalli, None
M. Costandi, None
C. T. Makowski, None
B. Rezik, None
S. L. Davis, Achaogen: Scientific Advisor , Consulting fee . Allergan: Scientific Advisor , Consulting fee . Melinta: Scientific Advisor , Consulting fee . Nabriva: Scientific Advisor , Consulting fee . Zavante: Scientific Advisor , Consulting fee .